Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Nutr Clin Pract. 2020 Jun;35(3):487-494. doi: 10.1002/ncp.10477. Epub 2020 Mar 9.
Since the introduction of percutaneous endoscopic gastrostomy in the 1980s, the prevalence of home enteral nutrition (HEN) support has increased significantly. Despite these increases, many patients are unable to tolerate standard polymeric formulas (SPFs), resulting in significant healthcare resource utilization. Peptide-based diets (PBDs) have emerged as a viable option in SPF-intolerant patients; however, data in the HEN population are lacking.
Retrospective review of our prospectively maintained HEN database was conducted to assess tolerance, efficacy, and impact on healthcare utilization in patients on PBDs.
From January 1, 2016, to May 1, 2018, 95 patients were placed on PBDs, with 53 patients being started directly and 42 patients being transitioned from SPFs. In patients transitioned to PBDs, symptoms of nausea and vomiting, diarrhea, abdominal pain, and distention improved significantly. Healthcare utilization also declined significantly, including mean number of phone calls (1.8 ± 1.6 to 1.1 ± 0.9, P = 0.006), mean number of emergency room visits (0.3 ± 0.6 to 0.09 ± 0.3, P = 0.015), and mean number of provider visits (1.3 ± 1.3 to 0.3 ± 0.5, P < 0.0001).
Overall, PBDs were well tolerated and resulted in significant improvements in symptoms of gastrointestinal distress and healthcare utilization in patients intolerant to SPFs.
自 20 世纪 80 年代引入经皮内镜胃造口术以来,家庭肠内营养(HEN)支持的患病率显著增加。尽管有所增加,但许多患者无法耐受标准聚合物配方(SPF),导致大量医疗资源被利用。基于肽的饮食(PBD)在 SPF 不耐受患者中已成为一种可行的选择;然而,在 HEN 人群中缺乏相关数据。
对我们前瞻性维护的 HEN 数据库进行回顾性审查,以评估 PBD 不耐受患者的耐受性、疗效以及对医疗保健利用的影响。
从 2016 年 1 月 1 日至 2018 年 5 月 1 日,95 名患者开始使用 PBD,其中 53 名患者直接开始使用,42 名患者从 SPF 转换而来。在转为 PBD 的患者中,恶心和呕吐、腹泻、腹痛和腹胀等症状明显改善。医疗保健利用也显著下降,包括平均电话次数(1.8±1.6 次至 1.1±0.9 次,P=0.006)、平均急诊就诊次数(0.3±0.6 次至 0.09±0.3 次,P=0.015)和平均就诊次数(1.3±1.3 次至 0.3±0.5 次,P<0.0001)。
总体而言,PBD 耐受性良好,可显著改善 SPF 不耐受患者的胃肠道不适症状和医疗保健利用。